Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
As of close of business last night, Neogenomics Inc’s stock clocked out at $14.66, up 1.10% from its previous closing price of $14.50. In other words, the price has increased by $1.10 from its previous closing price. On the day, 0.62 million shares were traded. NEO stock price reached its highest trading level at $14.68 during the session, while it also had its lowest trading level at $14.04.
Ratios:
To gain a deeper understanding of NEO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.91 and its Current Ratio is at 1.99. In the meantime, Its Debt-to-Equity ratio is 0.67 whereas as Long-Term Debt/Eq ratio is at 0.44.
On December 10, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $22.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 15 ’24 when Olivo Alicia C sold 5,175 shares for $15.36 per share. The transaction valued at 79,475 led to the insider holds 37,129 shares of the business.
ALICIA OLIVO bought 5,175 shares of NEO for $81,713 on Nov 15 ’24. On Aug 15 ’24, another insider, Olivo Alicia C, who serves as the General Counsel of the company, sold 1,040 shares for $16.05 each. As a result, the insider received 16,695 and left with 43,813 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NEO now has a Market Capitalization of 1881772288 and an Enterprise Value of 2100225408. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.92 while its Price-to-Book (P/B) ratio in mrq is 2.07. Its current Enterprise Value per Revenue stands at 3.261 whereas that against EBITDA is -4698.491.
Stock Price History:
The Beta on a monthly basis for NEO is 1.22, which has changed by -0.07110828 over the last 52 weeks, in comparison to a change of 0.24440956 over the same period for the S&P500. Over the past 52 weeks, NEO has reached a high of $19.11, while it has fallen to a 52-week low of $12.12. The 50-Day Moving Average of the stock is -10.97%, while the 200-Day Moving Average is calculated to be -3.21%.
Shares Statistics:
It appears that NEO traded 863.34K shares on average per day over the past three months and 1659250 shares per day over the past ten days. A total of 128.06M shares are outstanding, with a floating share count of 126.84M. Insiders hold about 1.18% of the company’s shares, while institutions hold 97.50% stake in the company. Shares short for NEO as of 1735603200 were 3861128 with a Short Ratio of 4.47, compared to 1732838400 on 3686439. Therefore, it implies a Short% of Shares Outstanding of 3861128 and a Short% of Float of 4.17.
Earnings Estimates
The stock of Neogenomics Inc (NEO) is currently drawing attention from 14.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is $0.02, with high estimates of $0.07 and low estimates of -$0.01.
Analysts are recommending an EPS of between $0.14 and $0.08 for the fiscal current year, implying an average EPS of $0.1. EPS for the following year is $0.2, with 14.0 analysts recommending between $0.27 and $0.13.
Revenue Estimates
In the current quarter, 9 analysts expect revenue to total $173.28M. It ranges from a high estimate of $174.4M to a low estimate of $172.4M. As of the current estimate, Neogenomics Inc’s year-ago sales were $155.55MFor the next quarter, 9 analysts are estimating revenue of $173.06M. There is a high estimate of $175.57M for the next quarter, whereas the lowest estimate is $169.3M.
A total of 9 analysts have provided revenue estimates for NEO’s current fiscal year. The highest revenue estimate was $662.9M, while the lowest revenue estimate was $661M, resulting in an average revenue estimate of $661.85M. In the same quarter a year ago, actual revenue was $591.64MBased on 12 analysts’ estimates, the company’s revenue will be $733.01M in the next fiscal year. The high estimate is $740.45M and the low estimate is $725.4M.
